alzheon, Author at Alzheon | Preserving Future Memories - Page 4 of 21

About alzheon

This author has not yet filled in any details.
So far alzheon has created 202 blog entries.

13 Jul, 2023

Venture Capitalists Fund New Generation of Alzheimer’s Drugs

alzheon2024-06-06T17:58:07-04:00July 13th, 2023|Tags: WSJ|

11 Jul, 2023

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Positive Biomarker/Clinical Correlations from Phase 2 Biomarker Study at Alzheimer’s Association International Conference in Amsterdam

alzheon2024-08-12T09:43:10-04:00July 11th, 2023|

27 Jun, 2023

Advances in AD Treatments

alzheon2023-07-20T10:28:14-04:00June 27th, 2023|

27 Jun, 2023

Part 2: APOE Genotyping in Clinical Practice: Pros and Cons

alzheon2023-07-20T10:30:08-04:00June 27th, 2023|

27 Jun, 2023

Part 1: The Role of APOE Genotyping in Alzheimer’s Disease Risk Stratification

alzheon2023-07-20T10:29:35-04:00June 27th, 2023|

27 Jun, 2023

Unprecedented Reduction in Key Alzheimer’s Biomarker for Patients Treated With ALZ-801

alzheon2023-07-28T10:07:13-04:00June 27th, 2023|

27 Jun, 2023

A First of Its Kind, ALZ-801 Aims To Preserve Memories, Save Lives: An Exclusive Interview with Dr. Martin Tolar

alzheon2023-07-27T17:26:57-04:00June 27th, 2023|

27 Jun, 2023

The Science Behind the Drug That May Stop Alzheimer’s Disease in Its Tracks

alzheon2023-07-17T13:26:16-04:00June 27th, 2023|

10 May, 2023

Understanding Patient Characteristics of Phase 3 APOLLOE4 Trial of ALZ-801 in Alzheimer Disease: John Hey, PhD

alzheon2023-05-31T18:05:53-04:00May 10th, 2023|

6 May, 2023

Eli Lilly’s Donanemab: The Anti-Amyloid Saga Continues

alzheon2023-07-31T15:59:29-04:00May 6th, 2023|